78 related articles for article (PubMed ID: 23902290)
1. Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers.
Hariprasad G; Hariprasad R; Kumar L; Srinivasan A; Kola S; Kaushik A
Biomarkers; 2013 Sep; 18(6):532-41. PubMed ID: 23902290
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling of peritoneal rinse fluid sediment separates patients with ovarian cancer from women admitted for cesarean section. A pilot study.
Honoré B; Vorum H; Knudsen A
Scand J Clin Lab Invest; 2010 Nov; 70(7):470-7. PubMed ID: 20704521
[TBL] [Abstract][Full Text] [Related]
3. Protein expression patterns associated with advanced stage ovarian cancer.
Cortesi L; Rossi E; Della Casa L; Barchetti A; Nicoli A; Piana S; Abrate M; La Sala GB; Federico M; Iannone A
Electrophoresis; 2011 Aug; 32(15):1992-2003. PubMed ID: 21728179
[TBL] [Abstract][Full Text] [Related]
4. Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics.
Shield-Artin KL; Bailey MJ; Oliva K; Liovic AK; Barker G; Dellios NL; Reisman S; Ayhan M; Rice GE
Proteomics Clin Appl; 2012 Apr; 6(3-4):170-81. PubMed ID: 22532453
[TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients.
Hantke B; Harbeck N; Schmalfeldt B; Claes I; Hiller O; Luther MO; Welk A; Kuhn W; Schmitt M; Tschesche H; Muehlenweg B
Biol Chem; 2003 Aug; 384(8):1247-51. PubMed ID: 12974393
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer.
Kim S; Cho H; Nam EJ; Kim SW; Kim YT; Park YW; Kim BW; Kim JH
Genes Chromosomes Cancer; 2010 Jul; 49(7):585-95. PubMed ID: 20461751
[TBL] [Abstract][Full Text] [Related]
9. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer.
Borgoño CA; Grass L; Soosaipillai A; Yousef GM; Petraki CD; Howarth DH; Fracchioli S; Katsaros D; Diamandis EP
Cancer Res; 2003 Dec; 63(24):9032-41. PubMed ID: 14695222
[TBL] [Abstract][Full Text] [Related]
10. Proteomics and biomarkers for ovarian cancer diagnosis.
Zhang B; Barekati Z; Kohler C; Radpour R; Asadollahi R; Holzgreve W; Zhong XY
Ann Clin Lab Sci; 2010; 40(3):218-25. PubMed ID: 20689132
[TBL] [Abstract][Full Text] [Related]
11. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
12. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma.
Morita A; Miyagi E; Yasumitsu H; Kawasaki H; Hirano H; Hirahara F
Proteomics; 2006 Nov; 6(21):5880-90. PubMed ID: 17022098
[TBL] [Abstract][Full Text] [Related]
13. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins.
Li B; An HJ; Kirmiz C; Lebrilla CB; Lam KS; Miyamoto S
J Proteome Res; 2008 Sep; 7(9):3776-88. PubMed ID: 18642944
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
[TBL] [Abstract][Full Text] [Related]
15. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
Ye B; Skates S; Mok SC; Horick NK; Rosenberg HF; Vitonis A; Edwards D; Sluss P; Han WK; Berkowitz RS; Cramer DW
Clin Cancer Res; 2006 Jan; 12(2):432-41. PubMed ID: 16428483
[TBL] [Abstract][Full Text] [Related]
16. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer: biomarker proteomic diagnosis in progress.
Zhang Y; Guo B; Bi R
Appl Biochem Biotechnol; 2012 Oct; 168(4):910-6. PubMed ID: 22945560
[TBL] [Abstract][Full Text] [Related]
18. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
Jurisicova A; Jurisica I; Kislinger T
Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells.
Forster MD; Ormerod MG; Agarwal R; Kaye SB; Jackman AL
Cytometry A; 2007 Nov; 71(11):945-50. PubMed ID: 17712798
[TBL] [Abstract][Full Text] [Related]
20. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.
Connor JP; Felder M
Gynecol Oncol; 2008 Nov; 111(2):330-5. PubMed ID: 18723214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
